Swander Pace exits OTC healthcare company to trade partner in $750m deal


download (11)Private equity firm Swander Pace Capital has agreed to sell over-the-counter products company Insight Pharmaceuticals to strategic investor Prestige Brands Holdings for $750m.

Consumer-focused Swander Pace first invested in Insight in 2009 and since then the company’s sales have more than doubled, from approximately $80m to more than $200m.

The sale of Insight to fellow OTC pharma products company Prestige represents the Swander’s second successful exit in the OTC industry, said the firm.

Other investors in Insight included the Ontario Teachers’ Pension Plan.

Insight has around 30 products in its portfolio. These include women’s health and personal care products such as home pregnancy testing brand e.p.t.

Swander Pace managing director Corby Reese said, “Through focused brand development, cost improvements, and strategic acquisitions, we were able to grow the company’s sales by more than 150 per cent and provide an exceptional return on investment for our investors.”

The firm closed its fifth fund on $350m in April this year making it the largest vehicle raised by the private equity firm to date.

Its predecessor fund closed on $340m in 2008.

Copyright © 2014 AltAssets